Perspective

Beyond prostate, beyond surgery and beyond urology: The “3Bs” of managing non-neurogenic male lower urinary tract symptoms

Qixiang Song a, Paul Abrams b,*, Yinghao Sun a,*

a Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China
b Bristol Urological Institute, Southmead Hospital, Bristol, UK

Received 27 July 2017; received in revised form 16 August 2017; accepted 30 August 2017
Available online 23 November 2017

KEYWORDS
Male; Lower urinary tract symptoms; Benign prostatic hyperplasia; Benign prostatic obstruction; Detrusor overactivity; Detrusor underactivity; Prostate surgery; Comorbidities

Abstract Lower urinary tract symptoms (LUTS), consisting storage, voiding and post-micturition symptoms, is a comprehensive definition involving symptoms that may occur due to several causes. Instead of simply focusing on the enlarged prostate, more attention has to be paid to the entire urinary tract as well as multiple system comorbidities. Therefore, prostate surgery alone does not necessarily provide adequate management and cross-disciplinary collaborations are sometimes required. Based on current literature, this paper proposes the “3Bs” concept for managing non-neurogenic male LUTS, namely, “beyond prostate”, “beyond surgery” and “beyond urology”. The clinical application of the “3Bs” enables urologists to carry out integrated, individualized and precise medical care for each non-neurogenic male LUTS patient.

ª 2019 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

It has become increasingly evident that “lower urinary tract symptoms” (LUTS) is a comprehensive term, encompassing storage, voiding and post-micturition symptoms, and was proposed more than 20 years ago to emphasize that there are other causes than the prostate for LUTS [1,2]. Over the past decade, the European Association of Urology (EAU) has replaced the title "Guidelines on benign prostatic hyperplasia (BPH) " with "Guidelines on the treatment of non-neurogenic male LUTS", in 2011, and now in 2017 the EAU Guidelines are “Guidelines on management of non-neurogenic male LUTS, incl. benign prostatic obstruction (BPO)” and have been since 2013 [3–6]. This major
modification has highlighted that the urinary tract should be viewed as a whole, and the treatments need to be tailored for each individual patient. In this new perspective, we propose the “3Bs” of managing non-neurogenic male LUTS based on a current literature review, namely, “beyond prostate”, “beyond surgery” and “beyond urology”.

2. Beyond prostate

Although the term LUTS is in universal use, the term BPH is still misused. In the literature there are many references that talk about the “BPH man” or “clinical BPH” but these terms have variable meanings and do not help patient management. In itself the histological appearance BPH does not cause LUTS. Also as the prevalence of histological BPH is very high: 50% in men at 50–60s and nearly 90% in men above 80 years, the term “BPH” used to describe a symptomatic man is meaningless in most men with LUTS. Only in a minority of men does histological BPH develop into benign prostatic enlargement (BPE), and then further progress to create BPO and cause LUTS (Fig. 1). Approximately 25% of men with histological BPH develop BPO. Although 50% of men with BPH develop BPE, only half go on to get BPO [7–10]. These data indicate that BPO causing LUTS should be distinguished from BPH and BPE which frequently exist, but do not cause LUTS in the absence of BPO. To emphasize this point, BPH is a histology diagnosis that correlates poorly with clinical symptoms [2]. Clinical experience also tells us a small prostate can sometimes cause severe obstruction, whereas a big prostate does not necessarily cause obstruction or LUTS. With that in mind, when the prostate is proved to be “innocent”, other possible causes of LUTS should to be taken into account, such as, overactive bladder due to detrusor overactivity during filling, detrusor underactivity (DU) during voiding, urethral stricture, stone diseases, and chronic pelvic pain syndrome, etc, depicted graphically (Fig. 2) in the 2017 EAU guidelines [6].

Moreover, patients with sustained BPO can also have bladder dysfunction which may be due to abnormalities of neurotransmitters, neuromodulators, receptors and signaling pathways in the urothelium, detrusor smooth muscle and/or interstitial cells [9]. Oelke and colleagues [11] demonstrated that of 1418 man with “clinical BPH”, detrusor overactivity (DO) was found in 864 patients (60.9%) and was independently associated with the grade of bladder outlet obstruction. In another study on 2039 "LUTS/BPH" patients, 58.7% of them presented DU during urodynamic studies [12]. DO can give rise to bothersome overactive bladder storage symptoms (urgency, frequency, urgency incontinence and nocturia), while DU leads to voiding symptoms (weak stream and dysuria) which can only be distinguished from BPO using an invasive pressure-flow study.

In addition, BPO related lower urinary tract dysfunction can jeopardize the upper urinary tract. Traditionally, using serum creatinine as the diagnostic criteria for chronic kidney diseases (CKD), 11% of “BPH” patients also had impaired renal function [13]. Note that compared to serum creatinine, estimated glomerular filtration rate (eGFR) is a more sensitive and accurate indicator because it takes age, sex, race and cystatin C into account [14,15]. More recently, different studies have reported that among male LUTS patients, 18.0%–31.9% of them demonstrated moderate to severe eGFR reduction (<60 mL/min/1.73 m²) [16,17]. In this regard, when dealing with the lower urinary tract abnormalities, it is wise to stay vigilant at all times on patients’ upper urinary tract as well, and follow the EAU recommendation that ultrasound of the urinary tract and renal assessment should be done when indicated, for example when there is a large post void residual.

From the aforesaid, when faced with a man with LUTS it is possible that the man’s symptom complex could be associated with disease progression and the development of complications. Instead of simply focusing on the enlarged
prostate, we need to see a bigger picture and probably shift our conventional notion of “BPH” to “bladder, prostate and kidney (BPK)” when managing male LUTS patients (Fig. 3A).

3. Beyond surgery

Conventionally, patients with increased prostate volume would have been labelled as candidates for surgery without hesitation. However over the past 2 decades, studies from different countries have reported that the rate of both open and minimal invasive prostate surgery has been decreasing each year. A survey based on national inpatient database (represents roughly one-fifth of the total inpatients of the United States) demonstrated that the total usage of prostate surgeries decreased between year 2002 through 2012 (from about 4000 to 2500 cases per year) [18]. In Iceland, the application of transurethral resection of the prostate (TURP) on men with “BPH” over 50 peaked in 1992 (30 procedures per 1000 men), then gradually reduced each year and ended at 3.4 procedures per 1000 men in 2008 [19]. Furthermore, a report from Spain also showed a 17.6% decrease in benign prostate surgery from 1992 to 2002 [20].

Why are fewer prostatectomies being performed?

The first and probably the most straightforward explanation for this phenomenon is the introduction of medical therapy. One of the above mentioned studies indicated that the descending trend of TURP procedures carried out since 1992 was accompanied by an ascending adoption of α1-adrenergic antagonists and 5α-reductase inhibitors which are both first line agents recommended by the EAU guidelines [6,19]. Besides, the use of muscarinic receptor antagonists, phosphodiesterase type 5 inhibitors and β3-adrenergic agonists, and mono- or combination therapy offer alternative options. Therefore, patients who used to be treated by surgery are being given oral medications. Moreover, behavioural and lifestyle self-managing are being increasingly offered to patients concurrently with watchful waiting and standard treatment as recommended by the EAU guidelines [6]. A randomized control study indicated that patients allocated to self-managing group experienced lower treatment failure rate, less symptom severity, and higher quality of life than those without [21]. However, whether self-management, on its own, can reduce or postpone the need for surgery remains unclear.

Additionally, surgery should now be reserved for "Mr. Right" who presents with bothersome LUTS attributed to BPO, possibly refractory to conservative/medical treatment. Note that performing TURP on unobstructed patients, or those with LUTS due to DU does not yield superior outcomes in both urodynamic parameters and symptoms compared to those who have no treatment [22]. In addition, though TURP substantially improves maximum flow rate, International Prostate Symptom Score (IPSS) and quality of life, the incidence of unrelieved postsurgical storage symptoms is 31%–59% at 6 months follow-up and up to 10% patients report de novo DO [23]. Thus, surgery can only achieve its maximum benefits in carefully selected patients and even then post-surgical medication treatment may be needed.

Last but not the least, the emerging new technologies provide much less invasive solutions and may have potential impact on current treatment paradigms. These novel technologies include prostatic urethral lift, radio-frequency generated thermal therapy, aquablation, prostatic artery embolization, implantable nitinol device, and electromagnetic field therapy, just to name a few [24]. Generally, these approaches are minimal or non-invasive with less morbidity, have very short or no hospitalization and can be done under local anesthesia. Though sufficient data have validated their initial efficacy and safety, more randomized control trials are required to elucidate their long-term equivalence or superiority over the existing endoscopic procedures.

![Figure 3](image-url) Figure 3 Schematic illustrated the "3Bs" of managing non-neurogenic male lower urinary tract symptoms, i.e., beyond prostate (A), beyond surgery (B) and beyond urology (C). The bullet points in the right column represent examples of the pointed categories in the circles. 5αRI, 5α-reductase inhibitors; BPK, bladder prostate and kidney; BPO, benign prostatic obstruction; BPH, benign prostatic hyperplasia; CKD, chronic kidney diseases; DO, detrusor overactivity; DU, detrusor underactivity; PDE5I, phosphodiesterase type 5 inhibitors.
In short, we have versatile treatment options beyond surgery and they must be individualized based on clinical findings and the degree of symptom bother (Fig. 3B).

4. Beyond urology

Numerous data exists to demonstrate that LUTS is highly related to lifestyle factors, systemic disorders and geriatric diseases (Fig. 3C). Heavy smokers are prone to have more severe LUTS and significant symptom deterioration, but sufficient daily physical activity reduces LUTS exacerbation during follow-up [25,26]. Reports from the International Consultation on Incontinence Research Society revealed that LUTS and metabolic syndrome (comprising cardiological aberrations, hypertension, central obesity, dyslipidemia and type 2 diabetes) share multiple pathophysiological mechanisms and correlate with each other [27]. In addition, chronic obstructive pulmonary disease is associated with an increased incidence of “BPH”, and urgency urinary incontinence is the predominant LUTS in these patients [28,29]. Furthermore, anthropometric, psychological, and hormonal factors should also be taken into consideration during management [7].

Nocturia is a good example to illustrate the multifactorial feature of LUTS. (1) Patients with congestive heart failure, chronic renal insufficiency, hepatic failure, nephrotic syndrome, autonomic neuropathy or hypoalbuminemia may have third-space fluid sequestration which can result in nocturia due to nocturnal polyuria, when more than 33% of the 24 h urine volume is produced at night. (2) Circadian secretion of arginine vasopressin can be compromised when there are hypothalamic–pituitary axis abnormalities which can also lead to nocturia. (3) Sleeping disorders (such as, restless leg syndrome and obstructive sleep apnoea) are also highly related to increased nighttime urinary frequency. (4) Patients with reduced renal function, uncontrolled diabetes mellitus or diabetes insipidus may have 24 h polyuria, generating both daytime frequency and nocturia. (5) Modification of some living habits, including reducing evening fluid intake, stopping smoking and vigorous physical exercise, can alleviate nocturia and improve quality of life [30,31].

Hence one can see that urologists need to think beyond urology and seek cross-disciplinary collaborations so as to offer sufficient clinical care for patients with LUTS and associated comorbidities.

To sum up, “beyond prostate” highlights the importance of keeping an eye on the bladder function and upper urinary tract; “beyond surgery” emphasizes that we have various choices of self-management strategies, medications and novel approaches which should be personalized accordingly; and “beyond urology” reminds us that LUTS has multifactorial causes including systematic comorbidities. The clinical application of the “3Bs” enables urologists to carry out integrated, individualized and precise medical care for non-neurogenic male LUTS patients.

Author contributions

Study concept and design: Qixiang Song, Paul Abrams, Yinghao Sun.

Data acquisition: Qixiang Song.

Drafting manuscript: Qixiang Song.

Critical revision of the manuscript: Qixiang Song, Paul Abrams, Yinghao Sun.

Final approval of manuscript: Qixiang Song, Paul Abrams, Yinghao Sun.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgements

The authors gratefully acknowledge the permission from the EAU guidelines office to publish Fig. 2 in this paper.

References

[1] Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.
[2] Abrams P. New words for old: lower urinary tract symptoms for “prostatism. BMJ 1994;308:929–30.
[3] de la Rosette J, Alivizatos G, Madersbacher S, Rioja Sanz C, Nordling J, Emberton M, et al. Guidelines on benign prostatic hyperplasia. 2009. https://uroweb.org/wp-content/uploads/EAU-Guidelines-BPH-2009.pdf.
[4] Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. Guidelines on the treatment of non-neurogenic male LUTS. 2011. https://uroweb.org/wp-content/uploads/12_Male_LUTS.pdf.
[5] Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. Guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2013. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-LUTS-2013.pdf.
[6] Gravas S, Bach T, Dake M, Gacci M, Gratzke C, Herrmann TRW, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). 2017. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5.
[7] Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49:651–8.
[8] Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005;7(Suppl 9):S3–14.
[9] Soler R, Andersson KE, Chancellor MB, Chapple CR, de Groat WC, Dake MJ, et al. Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:610–21.
[10] Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–9.
[11] Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Hofner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008;54:419–26.
[12] Kang M, Kim M, Choo MS, Paick JS, Oh SJ. Urodynamic features and significant predictors of bladder outlet obstruction in patients with lower urinary tract symptoms/benign prostatic
hyperplasia and small prostate volume. Urology 2016;89:96–102.

[13] Gerber GS, Goldfscher ER, Karrison TG, Bales GT. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 1997;49:697–702.

[14] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:51–266.

[15] Stevens PE, Levin A, Group KDIGOCKDGWDW. Evaluation and management of chronic kidney disease: synopsis of the global 2012 clinical practice guideline. Ann Intern Med 2013;158:825–30.

[16] Hong SK, Lee ST, Jeong SJ, Byun S-S, Hong YK, Park DS, et al. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int 2010;105:1424–8.

[17] Yamasaki T, Naganuma T, Iguchi T, Kuroki Y, Kuwabara N, Takemoto Y, et al. Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia. Nephrol Carlt 2011;16:335–9.

[18] Pariser JJ, Pearce SM, Patel SG, Bales GT. National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology 2015;86:721–5.

[19] Ingimarsson JP, Isaksson HJ, Sigbjarnarson HP, Gudmundsson J, Geirsson G. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate. Scand J Urol 2014;48:73–8.

[20] Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Saras-Corrall JL, Granizo JJ. The impact of medical therapy on surgery for benign prostate hyperplasia: a study comparing changes in a decade (1992–2002). BJU Int 2005;96:1045–8.

[21] Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007;334:25. https://doi.org/10.1136/bmj.39010.551319.

[22] Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004;93:745–50.

[23] Housami F, Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep 2008;9:284–90.

[24] Sievert KD, Kuntit T. Emerging techniques in ‘truly’ minimal-invasive treatment options of benign prostatic obstruction. Curr Opin Urol 2017;27:287–92.

[25] Choo MS, Han JH, Shin TY, Ko K, Lee WK, Cho ST, et al. Alcohol, smoking, physical activity, protein, and lower urinary tract symptoms: prospective longitudinal cohort. Int Neurourol J 2015;19:197–206.

[26] Bolat MS, Akdeniz E, Ozkaya S, Batur AF, Kutman KG, Goren R, et al. Smoking and lower urinary tract symptoms. Urol J 2015;12:2447–51.

[27] Denys MA, Anding R, Tubaro A, Abrams P, Everaert K. Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014. Neurourol Urodyn 2016;35:278–82.

[28] Hirayama F, Lee AH, Binns CW, Taniguchi H, Nishimura K, Kato K. Urinary incontinence in men with chronic obstructive pulmonary disease. Int J Urol 2008;15:751–3.

[29] Peng YH, Huang CW, Liao WC, Chen HJ, Yin MC, Huang YM, et al. Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study. BMJ open 2017;7:e015581. https://doi.org/10.1136/bmjopen-2016-015581.

[30] Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn 2014;133 Suppl:S2–5.

[31] Weiss JP, Bosch JL, Drake M, Dmochowski RR, Hashim H, Hijaz A, et al. Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn 2012;31:330–9.